<DOC>
	<DOCNO>NCT02610296</DOCNO>
	<brief_summary>The purpose trial evaluate reduction incidence severity delay graft function kidney allograft donor &gt; 45 year brain death ( DBD ) .</brief_summary>
	<brief_title>QPI-1002 Prevention Delayed Graft Function Recipients Older Donor Kidney Transplant</brief_title>
	<detailed_description>This Phase 3 randomize , placebo-controlled , double-blind , multi-center trial stratify donor age region evaluate reduction incidence severity delay graft function kidney allograft DBD donor least 45 year age .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>Has ability understand requirement study , able provide write informed consent willing able comply requirement study protocol . Male female least 18 year age . Has dialysis dependent renal failure initiate least 2 month prior transplantation . Is recipient transplant decease donor ( brain death criterion ) ≥ 45 year age . Based donor age , follow requirement risk DGF ( determine use Irish DGF risk assessment nomogram ) cold ischemia time ( CIT ) must meet : Donor age 45 59 year : estimate DGF risk ≥ 20 % estimate CIT ≥ 10 hour Donor age ≥ 60 year : minimum estimate DGF risk minimum estimate CIT Is able comply requirement antibody induction therapy rabbit polyclonal antithymocyte globulin antiCD25 ( antiIL2R ) monoclonal antibody per center standard care . Must uptodate cancer screen accord sitespecific guideline past medical history must negative biopsyconfirmed malignancy within 5 year randomization , exception adequately treat basal cell squamous cell carcinoma situ carcinoma cervix situ . Recipient live donor kidney kidney donation cardiac death ( DCD ) donor . Recipient donor kidney preserve normothermic machine perfusion . Scheduled undergo multiorgan transplantation . Has plan transplant kidney implant en bloc ( dual kidney transplant ) . Has plan transplant dual kidney ( donor ) transplant en bloc . Has lose first kidney transplant due graft thrombosis . Is schedule transplantation kidney donor know receive investigational therapy another IND/CTA ischemic/reperfusion injury immediately prior organ recovery . Is schedule receive ABOincompatible donor kidney . Has positive T Bcell crossmatch NIH antiglobulin lymphocytotoxicity method CDC crossmatch method , perform . Has positive T Bcell flow crossmatch AND donor specific antiHLA antibody ( DSA ) detect flow cytometry , Luminex® base antigenspecific antiHLA antibody test , similar methodology , perform . Has undergone desensitization remove donor specific antiHLA antibody prior transplantation . Has participate investigational study within last 30 day receive investigational product within 5 halflives study drug administration , whichever long . Has know allergy participate prior study siRNA . Has history HBV ( Note : subject serological profile suggestive clearance , prior antiviral treatment prior HBV infection , may enrol approval Medical Monitor ) . Has history HIV . Recipient known HIV positive donor kidney . Is HCVpositive ( detectable HCV RNA ) ( Note : Subjects least 24 week completion treatment approve antiviral regimen remain free HCV determine HCV RNA test may enrol . Subjects clear HCV virus treatment unapproved regimen approve Medical Monitor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>